SG11202111678WA - Crystalline form of sofpironium bromide and preparation method thereof - Google Patents

Crystalline form of sofpironium bromide and preparation method thereof

Info

Publication number
SG11202111678WA
SG11202111678WA SG11202111678WA SG11202111678WA SG11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA
Authority
SG
Singapore
Prior art keywords
compound
crystalline form
content
crystalline
preparation
Prior art date
Application number
SG11202111678WA
Other languages
English (en)
Inventor
Kazuyoshi MARUBAYASHI
Masahito Watanabe
Herbert R Brinkman
Original Assignee
Kaken Pharma Co Ltd
Brickell Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Brickell Biotech Inc filed Critical Kaken Pharma Co Ltd
Publication of SG11202111678WA publication Critical patent/SG11202111678WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147Saturated compounds having only one carboxyl group and containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202111678WA 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof SG11202111678WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (1)

Publication Number Publication Date
SG11202111678WA true SG11202111678WA (en) 2021-11-29

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111678WA SG11202111678WA (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7417147B2 (en) * 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
EP3494106B1 (en) * 2016-08-02 2022-07-20 Journey Medical Corporation Processes for making, and methods of using, glycopyrronium compounds
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof

Also Published As

Publication number Publication date
JP2020189856A (ja) 2020-11-26
IL288285B1 (en) 2026-02-01
TW202110796A (zh) 2021-03-16
CA3139948A1 (en) 2020-11-26
US20210395197A1 (en) 2021-12-23
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
CN114008023A (zh) 2022-02-01
ZA202109514B (en) 2023-12-20
US11566000B2 (en) 2023-01-31
CL2021003047A1 (es) 2022-09-20
AU2020277881B2 (en) 2025-03-06
CO2021017456A2 (es) 2022-01-17
US11584715B2 (en) 2023-02-21
EP3972955A4 (en) 2023-07-05
TW202411205A (zh) 2024-03-16
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
IL288285A (en) 2022-01-01
BR112021023241A2 (pt) 2022-01-04
TWI870116B (zh) 2025-01-11
MX2021014163A (es) 2022-01-04
JP6748329B1 (ja) 2020-08-26
TWI838531B (zh) 2024-04-11
EP3972955A1 (en) 2022-03-30
JP7605598B2 (ja) 2024-12-24
US20220298108A1 (en) 2022-09-22
PH12021552915A1 (en) 2022-04-04
MY206154A (en) 2024-12-02
WO2020235665A1 (en) 2020-11-26
US20210171460A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
KR102888393B1 (ko) 신규한 염 및 결정
RU2771314C1 (ru) Производные хинолинпирролидин-2-она и их применение
EP2280955B1 (en) Crystalline form of 6-ý(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl¨pyridazin-3-amine
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
KR20170038850A (ko) (2s,3s)-메틸 7-플루오로-2-(4-플루오로페닐)-3-(1-메틸-1h-1,2,4-트리아졸-5-일)-4-옥소-1,2,3,4-테트라하이드로퀴놀린-5-카르복실레이트의 공형성체 염 및 이의 제조 방법
KR20250049276A (ko) 오비세트라피브(obicetrapib)의 염 및 그의 제조 방법 및 그의 중간체
WO2011091513A1 (en) Polymorphic forms of lubiprostone
TW201111387A (en) Novel crystal form of tricyclic benzopyran compound and production method thereof
US9643950B2 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
JP2024511614A (ja) フッ素置換ピリドピラゾール系化合物の結晶形及びその製造方法
KR20230026384A (ko) 화합물의 결정 형태
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
HK40118106A (zh) 奥比塞匹布的盐及其制备方法和中间体
AU2023359635A1 (en) Polymorphs of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof
HK40076742B (zh) 新型三苯基化合物盐
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)